Last month I joined tens of thousands of other advocates and cancer specialists at the annual meeting of the American Society of Clinical Oncology (ASCO). Like most, I hoped to learn about the newest research, and the latest breakthroughs in (lung) cancer. With my basic knowledge of science, I absorbed a lot of information about genetic mutations, targeted therapies, advancements in the development of novel agents, and in some cases the disappointment of what were thought to
